To the editor—The clinical, pathological, and genetic analyses of a Finnish pedigree (Finn2) with early-onset inherited Alzheimer disease (AD) have been reported1. This family demonstrated linkage to the PS1 region of chromosome 14, and analysis for PS1 mutations by RT–PCR and immunoblot demonstrated heterozygous deletion of exon 9, which has been shown to cause early-onset AD2. However, unlike a previously described family2, no splice acceptor site mutation was detected in Finn2, suggesting the presence of either a small genomic deletion that included exon 9 or of mutations elsewhere that could affect splicing.
Intronic primers flanking exon 9 were designed using the PAC sequence available in the Genbank sequence database (clone DJ0054D12; accession number AC006342). PCR amplification of an approximate 6.5-kb region encompassing exon 9 showed the presence of an aberrant product that segregated with affected members of Finn2 (Fig. 1) and was not present in more than 150 alleles of a Finnish control population over 85 years of age. This band was later confirmed by sequencing to be the result of a 4,555-bp deletion (which we call the Δ9 Finn variant) between exons 8 and 10 and encompassing exon 9. To our knowledge, this is the first time a deletion has been shown to cause an autosomal dominant neurodegenerative disorder. Despite the gross nature of the mutation, like other pathogenic presenilin mutations, this does not disrupt the overall structure of the protein.
The clinical, pathological and etiological importance of Δ9 mutations has been discussed1. In addition to the presence of 'cotton wool' plaques and the scarcity of congophilic cored plaques typical of AD, there seems to be an association with the PS1Δ9 or PS1Δ9 Finn mutations and the occurrence of spastic paraparesis. However, because spastic paraparesis has only been described in two of four families with Δ9 variations and because it may also be associated with other PS1 missense mutations3, the specific link between this symptom and Δ9 variations may be complex.
It will be useful to determine if other deletions exist in families in which Δ9 has been confirmed through RT–PCR or immunoblot experiments but in which splice-site mutations have not been found3. It is also important to check for this deletion in families in which early onset disease occurs but in which missense mutations have not been found, and in families whose members present with spastic paraparesis. If this precise deletion or similar deletions occur in other non-related families, it may indicate that a specific underlying mutation mechanism exists.
Finally, in addition to the obvious change at the protein level, we cannot exclude the possibility that the deletion seen in Δ9Finn also affects the transcriptional regulation, RNA stability or non-exon 9 splicing of PS1 in these families. Thus, there may be subtle phenotypic differences between Δ9Finn and Δ9 splice site mutations.
References
Crook, R. et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nature Med. 4, 452–455 (1998).
Perez-Tur, J. et al. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin 1 gene. NeuroReport 7, 204–207 (1995).
Kwok, J.B.J. et al. Two novel (M233T and R278T) presenilin 1 mutations in early onset Alzheimer's disease and preliminary evidence for association of presenilin 1 mutations with a novel phenotype. NeuroReport 8, 1537–1542 (1997).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prihar, G., Verkkoniem, A., Perez-Tur, J. et al. Alzheimer disease PS-1 exon 9 deletion defined. Nat Med 5, 1090 (1999). https://doi.org/10.1038/13383
Issue Date:
DOI: https://doi.org/10.1038/13383
This article is cited by
-
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Molecular Psychiatry (2022)
-
Genetics of dementia in a Finnish cohort
European Journal of Human Genetics (2018)
-
17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression
Molecular Psychiatry (2017)
-
Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease
Graefe's Archive for Clinical and Experimental Ophthalmology (2009)
-
Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene
Journal of Neurology (2006)